William J. Febbo Joins Myomo’s Board of Directors

Myomo Inc. has appointed William “Will” Febbo as a board director, to serve until the 2028 annual meeting of stockholders. With this appointment, the company now has six directors.

Febbo is an accomplished executive, entrepreneur, and investor with more than 30 years of experience in healthcare, financial services, and technology-driven businesses. He has successfully guided organizations through substantial growth, strategic transformations, acquisitions, and significant capital markets initiatives.

“We are pleased to welcome Will to our Board of Directors,” Myomo Chairman/CEO Paul R. Gudonis said. “I’m looking forward to Will’s contributions, particularly his expertise in scaling innovative direct-to-patient healthcare solutions, which is a key piece of strategy for 2026 and beyond. Additionally, his experience and credibility within capital markets should increase overall awareness of Myomo’s story as a solid investment thesis.”

Febbo is currently CEO and director of Performance Health Systems, a privately held company that uses health and wellness equipment to improve mobility for people at home, in businesses, and in clinics. Before joining Performance Health Systems in February, he was CEO of OptimizeRx Corporation from 2015 to 2024, where he transformed the company from a single point-of-care product provider into an artificial intelligence (AI)-driven omnichannel platform. Under his leadership, revenue grew from $5 million to $92 million, achieving a 41% five-year CAGR. He also led OptimizeRx’s uplisting from OTC to Nasdaq and expanded its digital healthcare network, contributing to significant growth in its market capitalization. Febbo has co-founded and led companies focused on the capital markets, including Merriman Holdings Inc., and Digital Capital Network.

Febbo earned a bachelor of arts degree in international studies and Spanish from Dickinson College. He is an MIT-affiliated faculty member and mentor in the linQ program, which supports biomedical innovation addressing major health and medical challenges. He also serves as a Mentor for the X & Y Class at Harvard Business School.

“My interest in Myomo stems from seeing the world adopting robotics within healthcare and looking for platforms which can scale and enable mobility for individuals in need. Myomo is poised to become a market leader in the field of advanced upper extremity orthotics,” Febbo stated. “I look forward to supporting the company’s continued product development and commercial growth. Focusing on building a platform to unlock additional value as it scales access to its technology for patients with upper extremity weakness or paralysis.”

Myomo Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line, a powered upper-limb orthosis that supports the arm and restores function to weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, or other neuromuscular disease or injury. It is currently the only marketed U.S. device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform daily living activities, including feeding themselves, carrying objects, and performing household tasks. Myomo is headquartered in Burlington, Mass., with sales and clinical professionals across the United States and representatives internationally.